Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology
Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology
https://www.nature.com/articles/s41375-026-03036-8
Publish Date: 2026-07-07 04:04:00
Source Domain: www.nature.com
Fu S, Wang M, Lairson DR, Li R, Zhao B, Du XL. Trends and variations in Mantle cell lymphoma incidence from 1995 to 2013: a comparative study between Texas and National SEER areas. Oncotarget. 2017;8:112516–29.
Google Scholar
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB, de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720–48.
Google Scholar
Morello L, Rattotti S, Giordano L, Jerkeman M, van Meerten T, Krawczyk K, et al. Mantle cell lymphoma of mucosa-associated lymphoid tissue: a European mantle cell lymphoma network study. Hemasphere. 2020;4:e302.
Google Scholar
Navarro A, Beà S, Jares P, Campo E. Molecular pathogenesis of Mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34:795–807.
Google Scholar
Jiang L, Ladetto M, Hermine O, Kluin-Nelemans JC, Walewski J, Doorduijn J, et al. Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020. Haematologica. 2025.
Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403:2293–306.
Google Scholar
Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F,…